Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haplo-SCT with PTCy for patients lacking matched donors
NCT03088709Phase 2Terminated
- Sponsor
- Loyola University Chicago
- Start
- Jan 2017
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cyclophosphamide in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), sponsored by Loyola University Chicago. Started Jan 2017; status: terminated.
02
Drugs
cyclophosphamide
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT03088709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03088709.